Format

Send to

Choose Destination
Future Oncol. 2015;11(5):853-64. doi: 10.2217/fon.14.285.

Pancreatic neuroendocrine tumors: a review.

Author information

1
The Gastrointestinal Unit, The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.

Abstract

Neuroendocrine tumors (NETs) are a rare and heterogeneous group of tumors with widely varying morphologies and behaviors. Due to their rarity and heterogeneity, progress in improving their treatment has been slow. However, in recent years there have been advances both in their characterization and in the available treatment options. This review will attempt to address these, with particular reference to pancreatic NETs. Pancreatic NETs are a subset of NETs, previously known as islet cell tumors, which appear to be a distinct biological entity, responding differently to systemic treatments compared with NETs arising elsewhere in the GI tract.

KEYWORDS:

DOTATATE; NETs; everolimus; neuroendocrine tumors; octreotide; pNETs; pancreatic NETs; somatostatin analogs; sunitinib

PMID:
25757686
DOI:
10.2217/fon.14.285
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center